S&P also affirmed the “A+” rating on Deaconess’ series 2011A, 2013A and 2015A fixed rate revenue bonds.
“The ‘A+’ rating continues to reflect our view of Deaconess’ exceptional pro forma maximum annual debt service, excellent business position, remarkable cash flow and improving balance sheet ratios,” said S&P analyst Brian Williamson.
The outlook is stable, reflecting S&P’s view that while Deaconess constructs a new patient tower and medical office building, it will maintain stellar operating performance, a solid balance sheet and a favorable business position.
More articles on healthcare finance:
HealthTrust taps iMedX, Zotec adds orthopedic client & more — 6 RCM keynotes
The clinician’s role in RCM: 3 questions with McKesson’s Dan Mowery
Craneware reports double-digit revenue growth in FY 2016
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
